Nathan A. Brooks

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer

Ryan L. Steinberg, Lewis J. Thomas, Nathan A. Brooks et al. · The Journal of Urology · 2019 · 174 citations

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks et al. · Molecular Cancer Therapeutics · 2013 · 115 citations

Drug Target, Antitumor Activity, P38 Mapk +20

Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors

Zhigang Wang, William Watt, Nathan A. Brooks et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2010 · 67 citations

Medicinal Chemistry, Caspase-8 Inhibition, Biochemistry +8

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design

Justin T. Matulay, Roger Li, Patrick J. Hensley et al. · The Journal of Urology · 2021 · 64 citations

IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease

Kirk A. Staschke, Sucai Dong, J. K. Saha et al. · The Journal of Immunology · 2009 · 54 citations · Full text